The influence of polymorphisms in the large group of MMP and TIMP genes on clinical outcomes in patients after ST elevation myocardial infarction (STEMI) treated with primary PCI was analysed. In total, 550 consecutive Caucasian patients with STEMI were included in the present study, with a median of 32 months. We analysed 19 polymorphisms in the genes coding MMP and TIMP genes. The MMP-1 -519A/G and -422A/T polymorphisms are associated with combined endpoint after myocardial infarction. The hazard ratio for AT variant of MMP-1 -422A/T was 1.75 (p < 0.001); the variants with at least one A allele of MMP-1 -519A/G have less risk of combined endpoint. The TT variants of -1562C/T MMP-9 and at least one T allele of +92C/T MMP-13 were considered in a trend to affect disease progression and long-term survival after myocardial infarction. According to reclassification analysis NRI and IDI, long-term risk stratification using MMP-1 -422A/T and -519A/G polymorphisms gives additional information to the commonly used GRACE risk score. Patient stratification after myocardial infraction (MI) according to risk genotypes of MMP-1 polymorphisms could have important clinical implications for identification of patients at risk and therapeutic strategies.

• Keywords
• MMP, Polymorphism, Prognosis, STEMI, TIMP,
• MeSH
• Alleles MeSH
• Adult MeSH
• ST Elevation Myocardial Infarction diagnosis   genetics   MeSH
• Percutaneous Coronary Intervention MeSH
• Middle Aged MeSH
• Humans MeSH
• Matrix Metalloproteinase 1 genetics   MeSH
• Matrix Metalloproteinase 13 genetics   MeSH
• Matrix Metalloproteinase 9 genetics   MeSH
• Polymorphism, Genetic MeSH
• Prognosis MeSH
• Risk Factors MeSH
• Aged MeSH
• Tissue Inhibitor of Metalloproteinases genetics   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Names of Substances
• Matrix Metalloproteinase 1 MeSH
• Matrix Metalloproteinase 13 MeSH
• Matrix Metalloproteinase 9 MeSH
• MMP1 protein, human MeSH Browser
• MMP13 protein, human MeSH Browser
• MMP9 protein, human MeSH Browser
• Tissue Inhibitor of Metalloproteinases MeSH

AIM: The purpose of this study is to determine the association between eotaxin 426 C/T, -384 A/G, 67 G/A, eNOS -786 T/C, 4 a/b, and MMP-13 rs640198 G/T and prognosis of patients with known CAD. METHODS: From total of 1161 patients referred to coronary angiography, 532 patients with angiographically confirmed CAD were selected. Their long-term outcome was followed up using hospital database. Subsequent events were assessed in this study: death or combined endpoint-myocardial infarction, unstable angina pectoris, revascularization, heart failure hospitalization, and cardioverter-defibrillator implantation. RESULTS: The multivariate Cox regression model identified age, smoking, and 3-vessel disease as significant predictors of all-cause death. Further analysis showed that eotaxin 67 G/A (GA + AA versus GG) and eotaxin -384 A/G (GG versus GA + AA) were significant independent prognostic factors when added into the model: HR (95% CI) 2.81 (1.35-5.85), p = 0.006; HR (95% CI) 2.63 (1.19-5.83), p = 0.017; eotaxin -384 A/G was significantly associated with the event-free survival, but it did not provide the prognostic information above the effect of two- or three-vessel disease. CONCLUSION: The A allele in eotaxin 67 G/A polymorphism is associated with worse survival in CAD patients.

• MeSH
• Chemokine CCL11 genetics   MeSH
• Polymorphism, Single Nucleotide * MeSH
• Middle Aged MeSH
• Humans MeSH
• Matrix Metalloproteinase 13 genetics   MeSH
• Coronary Artery Disease diagnosis   genetics   MeSH
• Aged MeSH
• Case-Control Studies MeSH
• Nitric Oxide Synthase Type III genetics   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Chemokine CCL11 MeSH
• Matrix Metalloproteinase 13 MeSH
• MMP13 protein, human MeSH Browser
• Nitric Oxide Synthase Type III MeSH